Adenosine-mediated killing of cultured epithelial cancer cells.
Because micromolar concentrations of adenosine (Ado) have been documented recently in the interstitial fluid of carcinomas growing in animals, we examined the effects of low concentrations of Ado on the growth of cultured human carcinoma cells. Ado alone had little effect upon cell growth. In the presence of one of a number of Ado deaminase (ADA) inhibitors, Ado led to significant growth inhibition of all cell lines tested. Similar effects were found when ATP, ADP, or AMP was substituted for Ado. Surprisingly, the ADA inhibitor coformycin (CF) had a much greater potentiating effect than did 2'-deoxycoformycin (DCF), although DCF is a more potent ADA inhibitor. The growth inhibition of the Ado/CF combination was not abrogated by pyrimidines or caffeine, a nonspecific Ado receptor blocker. Toxicity was prevented by the addition of the Ado transport inhibitor dipyridamole or the Ado kinase inhibitor 5'-amino 5'-deoxyadenosine. S-Adenosylhomocysteine hydrolase is not involved because neither homocysteine thiolactone nor an S-adenosylhomocysteine hydrolase inhibitor (adenosine dialdehyde) potentiated toxicity of the Ado/CF combination. Unexpectedly, substitution of 2'-deoxyadenosine (the toxic moiety in congenital ADA deficiency) for Ado, did not lead to equivalent toxicity. The Ado/CF combination inhibited DNA synthesis and brought about morphological changes consistent with apoptosis. Together, these findings indicate that the Ado-mediated killing proceeds via an intracellular route that requires the action of Ado kinase. The enhanced cofactor activity of CF may be attributable to its being a more potent inhibitor of AMP deaminase than is DCF.
Barry
C P
CP
Division of Hematology and Oncology, Evanston Northwestern Healthcare and Northwestern University Medical School, Illinois 60201, USA.
Lind
S E
SE
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D058892:Adenosine Deaminase Inhibitors; D000248:Adenosine Kinase / Q000037:antagonists & inhibitors; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms; D002294:Carcinoma, Squamous Cell; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects*; D003070:Coformycin / Q000633:toxicity*; D003839:Deoxyadenosines / Q000494:pharmacology; D004176:Dipyridamole / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D007700:Kinetics; D010051:Ovarian Neoplasms; D015649:Pentostatin / Q000633:toxicity*; D014407:Tumor Cells, Cultured
D058892:Adenosine Deaminase Inhibitors; D003839:Deoxyadenosines; D004791:Enzyme Inhibitors; D003070:Coformycin; C057928:5'-amino-5'-deoxyadenosine; C027579:periodate-oxidized adenosine; D015649:Pentostatin; C010192:9-(2-hydroxy-3-nonyl)adenine; D004176:Dipyridamole; D000248:Adenosine Kinase; D000225:Adenine; D000241:Adenosine